Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
MERCAPTOPURINE ANHYDROUS Cancer	The First Affiliated Hospital with Nanjing Medical University	P3	B (58)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Cancer	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	P2	B (58)
Rapamycin Cancer	Albert Einstein College of Medicine	P2	B (58)
Abiraterone Acetate Cancer	Exelixis	P3	B (57)
CYCLOSPORIN A Cancer	Children's Oncology Group	P3	B (57)
Venetoclax Cancer	AbbVie	P3	B (57)
ima203 Cancer	Immatics US, Inc.	P1/2	B (57)
Decitabine Cancer	Chinese PLA General Hospital	P3	B (56)
NEPENTHE Cancer	M.D. Anderson Cancer Center	P3	B (56)
Romiplostim Cancer	Ain Shams University	P3	B (56)
Zanzalintinib Cancer	Exelixis	P3	B (56)
Zofran Cancer	Fate Therapeutics	P3	B (56)
Inno-206 Cancer	Centocor, Inc.	P1	B (56)
aciclovir Cancer	Children's Oncology Group	P3	CCC (54)
LIDOCAINE Cancer	Imperial College London	P3	CCC (52)
Mebendazole Cancer	Health Clinics Limited	P3	CCC (52)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Cancer	Kura Oncology, Inc.	P2	CCC (52)
Hycamtin Cancer	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	P2	CCC (52)
TEONANACATL Cancer	Roswell Park Cancer Institute	P2	CCC (52)
(+)-VINCRISTINE Cancer	Children's Oncology Group	P2	CCC (52)
Doxycycline Cancer	Health Clinics Limited	P3	CCC (51)
Encorafenib Cancer	Strata Oncology	P2	CCC (51)
Vancomycin Cancer	M.D. Anderson Cancer Center	P2	CCC (51)
Capmatinib Cancer	Cancer Research UK	P2/3	CCC (50)
plx038 Cancer	Institut Curie	P2	CCC (49)

Showing 26 to 50 of 151 assets

PreviousPage 2 of 7Next